Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
2mg |
|
||
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
Purity: ≥98%
Alprostadil (also known as Prostaglandin-E1) is a naturally occurring prostaglandin and a potent vasodilator used in the treatment of infants with congenital heart defects to maintain the patency of the ductus arteriosus until palliative or corrective surgery can be performed. It has vasodilatory qualities and is also used as a medication to treat erectile dysfunction. Alprostadil increases arterial blood oxygenation in infants with defects limiting pulmonary blood flow (cyanotic). Alprostadil increases urine output, femoral arterial pulses, and arterial blood pH in newborns with defects limiting systemic blood flow. Continuous intraarterial or intravenous infusion is the recommended method of administering alprostadil. The recommended starting dose is typically 0.1 microgram/kg/min, with maintenance doses as low as 0.002 microgram/kg/min.
Targets |
Human Endogenous Metabolite; EP
|
---|---|
ln Vitro |
In the presence of VEGF (20 ng/mL), prostaglandin E1 (1 nM-10 μM; 48 hours) concentration-dependently reduces HUVEC proliferation (up to 100% inhibition) with an IC50 of 400 nM [2]. Prostaglandin E1 (1-5 μM; 12-18 hours) inhibits VEGF-induced HUVEC migration in a concentration-suspended manner with an IC of 50 500 nM [2]. Prostaglandin E1 (1-5 μM; 12-18 hours) is produced by suspension cells [2] Prostaglandin E1 (0.01-10 μM; 20 minutes) increases intracellular cAMP levels in HUVECs [2].
|
ln Vivo |
Scaffoldin E1 (20 ng/animal/day; subcutaneous injection for 4 days) significantly inhibited FGF-induced angiogenesis in mice [2]. Animal model: C57/bl6 female mice (6-8 weeks) were injected with Matrigel and heparin supplemented with aFGF [2] Dosage: 20 ng/day/animal Administration method: Micropump was placed subcutaneously for 4 days Results: Significantly reduced new blood vessels Formation process.
|
Animal Protocol |
C57/bl6 female mice (6-8 weeks) were injected with Matrigel supplemented with aFGF and heparin
20 ng/day/animal Minipump placed subcutaneously for 4 days |
References |
|
Molecular Formula |
C20H34O5
|
|
---|---|---|
Molecular Weight |
354.48
|
|
Exact Mass |
354.24
|
|
Elemental Analysis |
C, 67.77; H, 9.67; O, 22.57
|
|
CAS # |
745-65-3
|
|
Related CAS # |
Prostaglandin E1-d4;211105-33-8;Prostaglandin E1-d9;2342573-59-3
|
|
Appearance |
Solid powder
|
|
SMILES |
CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O
|
|
InChi Key |
GMVPRGQOIOIIMI-DWKJAMRDSA-N
|
|
InChi Code |
InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h12-13,15-17,19,21,23H,2-11,14H2,1H3,(H,24,25)/b13-12+/t15-,16+,17+,19+/m0/s1
|
|
Chemical Name |
7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.05 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.05 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.05 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: ≥ 2.5 mg/mL (7.05 mM) (saturation unknown) in 10% EtOH + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear EtOH stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 5: ≥ 2.5 mg/mL (7.05 mM) (saturation unknown) in 10% EtOH + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear EtOH stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.8210 mL | 14.1052 mL | 28.2103 mL | |
5 mM | 0.5642 mL | 2.8210 mL | 5.6421 mL | |
10 mM | 0.2821 mL | 1.4105 mL | 2.8210 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT00610051 | Not yet recruiting | Drug: Alfuzosin | Heart Failure | Biopeutics Co., Ltd | October 2023 | Phase 3 |
NCT05475717 | Completed | Drug: Alprostadil liposome injection |
Contrast-induced Acute Kidney Injury |
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
October 20, 2022 | Phase 2 |
NCT00324948 | Completed | Drug: Topical alprostadil (PGE-1) |
Sexual Dysfunction, Physiological | VIVUS LLC | September 2004 | Phase 2 |
NCT02889822 | Completed | Drug: Alprostadil Liposomes for Injection |
Cardiovascular Diseases | Guangzhou Yipinhong Pharmaceutical CO.,LTD |
March 2010 | Phase 1 |
NCT02628106 | Completed | Drug: Lipo-PGE1 | Diabetic Nephropathy | West China Hospital | December 2015 | Phase 4 |
PGE1 inhibits endothelial cell proliferation (A) HUVECs were treated for 48 h with the indicated concentrations of PGE1/α-cyclodextrin in the presence of 20 ng ml−1 VEGF. Br J Pharmacol . 2003 Jan;138(2):377-85. td> |
PGE1 inhibits endothelial cell migration. Br J Pharmacol . 2003 Jan;138(2):377-85. td> |
PGE1 inhibits in vitro angiogenesis. Br J Pharmacol . 2003 Jan;138(2):377-85. td> |